Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.06, delivering a surprise of 14.29%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Biodesix, which belongs to the Zacks Medi ...

Editor's note: Seeking Alpha is proud to welcome Jaime Perez as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.With over two decades of experience, Jaime is a former sell-side and buy-side equity research analyst with deep and extensive knowledge of the energy and clean technology sector. He is a long-only fundamental analyst focusing on small to mid-ca ...

Fiverr International Ltd. (NYSE:FVRR) Annual JPMorgan Global Technology, Media and Communications Conference May 13, 2025 3:50 PM ET Company Participants Micha Kaufman - Chief Executive Officer Ofer Katz - Chief Financial Officer Conference Call Participants Doug Anmuth - JPMorgan Doug Anmuth All right, we're going to go ahead and get started. I'm Doug Anmuth, J.P. Morgan's Internet Analyst. Very happy to have with us Fiverr's co-founder and CEO, Micha Kaufman, and CFO, Ofer Katz. Fiverr is a global marketp ...

Core Viewpoint - Dare Bioscience, Inc. reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.63, indicating an earnings surprise of 20.63% [1] Financial Performance - The company posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 95.83%, compared to revenues of $0.01 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has not been able to beat consensus revenue estimates [2] Stock Performance - Dare Bioscience shares have lost about 7.7% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.6 million in revenues, and for the current fiscal year, it is -$1.97 on $3.3 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Group 1 - Lexicon Pharmaceuticals reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of 30% [1] - The company posted revenues of $1.26 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.52%, compared to year-ago revenues of $1.13 million [2] - Lexicon shares have declined approximately 8.8% since the beginning of the year, while the S&P 500 has seen a decline of -0.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $2.37 million, and for the current fiscal year, it is -$0.37 on revenues of $15.43 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Lexicon has a Zacks Rank of 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6]

Company Performance - Spero Therapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of 54.55% [1] - The company posted revenues of $5.87 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.60%, compared to revenues of $9.27 million a year ago [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Spero Therapeutics shares have declined approximately 40.8% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on $11 million in revenues, and for the current fiscal year, it is -$2.32 on $60 million in revenues [7] - The estimate revisions trend for Spero Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Spero Therapeutics' stock performance [5]

Financial Performance - Lineage Cell reported a quarterly loss of $0.02 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.04 per share a year ago [1] - The company posted revenues of $1.5 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 31.73%, but showing a slight increase from $1.44 million year-over-year [2] - Over the last four quarters, Lineage Cell has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2][1] Stock Performance - Lineage Cell shares have declined approximately 4.7% since the beginning of the year, compared to a decline of 0.6% for the S&P 500 [3] - The current Zacks Rank for Lineage Cell is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $2.25 million, and for the current fiscal year, it is -$0.07 on revenues of $16.05 million [7] - The trend of estimate revisions for Lineage Cell is mixed, which could change following the recent earnings report [6] Industry Context - Lineage Cell operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 35% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designed to guide investors of all levels in their journey. Features include a The Pragmatic Investor Portfolio, weekly market update newsletter, actionable trades, technical analysis, and a chat room. Learn moreJames Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust ...

Group 1: Market Overview - Wall Street's uncertainty has diminished as trade war concerns with China and inflationary fears have eased, leading to increased investor confidence [1] - Inflation report showed a decline for the third consecutive month, with grocery prices experiencing the largest drop in nearly five years and gas prices falling for three months in a row [1] Group 2: First Solar (FSLR) - First Solar shares surged nearly 20% and are up 50% in May due to favorable solar incentives remaining intact and not being affected by budget cuts [2] - Wolfe upgraded FSLR to outperform, projecting potential earnings of $10 billion from 45X credits, equating to approximately $92 per share [2] - Deutsche Bank also provided a positive outlook, labeling FSLR as a 'safe one' amidst changes, with less impact from 45X credits [2] - FSLR's stock regained its 200-day moving average with trading volume increasing to five times the norm [2] Group 3: CoreWeave (CRWV) - CoreWeave is showing a classic IPO u-turn base structure, with shares gaining nearly 10% and approaching all-time highs ahead of earnings [3] - The company is recognized for providing substantial processing power for large-scale computing and AI, backed by institutional investors like Nvidia [3] - CRWV's performance is compared to Google's breakout from a similar structure, indicating strong potential for future growth [3] Group 4: Oklo (OKLO) - Oklo shares increased by over 10% following positive results from NuScale Power, a fellow nuclear small modular reactor company [5] - The company is expected to report earnings soon, with heightened interest due to the approval of NuScale by the US Nuclear Regulatory Commission [5] - The current political climate may expedite further approvals in the nuclear sector, especially with Chris Wright, a former OKLO board member, now serving as the US Secretary of Energy [5]

Group 1 - Gladstone Commercial Corporation (GLAD) has made a significant acquisition to expand its industrial portfolio, indicating a strategic focus on this sector [1] - The company is actively pursuing growth opportunities within the industrial real estate investment trust (REIT) space, which appears to be a sensible strategy [1] Group 2 - The investing group "Value In Corporate Events" provides insights on major corporate events such as IPOs, mergers & acquisitions, and earnings reports, aiming to identify the best investment opportunities [2] - The group covers approximately 10 major events each month, focusing on capitalizing on changes in corporate capital allocation [2]